CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Gossamer Bio (GOSS) Could Be 96% Undervalued After Its Seralutinib NDA Update

NDA FilingSeralutinibPositive
AI Analysis

Summary

Gossamer Bio received an update regarding its Seralutinib NDA submission. The article suggests the stock could be significantly undervalued based on this development.

Importance:5/10
Sentiment:
0.60
NDASeralutinibValuationRegulatory
Related Companies

Read the original article

Published by yahoo_finance on August 1, 2026 2:06 AM

Read Original